Skip to Content
Merck
  • Transient viral exposure drives functionally-coordinated humoral immune responses in HIV-1 post-treatment controllers.

Transient viral exposure drives functionally-coordinated humoral immune responses in HIV-1 post-treatment controllers.

Nature communications (2022-04-13)
Luis M Molinos-Albert, Valérie Lorin, Valérie Monceaux, Sylvie Orr, Asma Essat, Jérémy Dufloo, Olivier Schwartz, Christine Rouzioux, Laurence Meyer, Laurent Hocqueloux, Asier Sáez-Cirión, Hugo Mouquet
ABSTRACT

HIV-1 post-treatment controllers are rare individuals controlling HIV-1 infection for years after antiretroviral therapy interruption. Identification of immune correlates of control in post-treatment controllers could aid in designing effective HIV-1 vaccine and remission strategies. Here, we perform comprehensive immunoprofiling of the humoral response to HIV-1 in long-term post-treatment controllers. Global multivariate analyses combining clinico-virological and humoral immune data reveal distinct profiles in post-treatment controllers experiencing transient viremic episodes off therapy compared to those stably aviremic. Virally-exposed post-treatment controllers display stronger HIV-1 humoral responses, and develop more frequently Env-specific memory B cells and cross-neutralizing antibodies. Both are linked to short viremic exposures, which are also accompanied by an increase in blood atypical memory B cells and activated subsets of circulating follicular helper T cells. Still, most humoral immune variables only correlate with Th2-like circulating follicular helper T cells. Thus, post-treatment controllers form a heterogeneous group with two distinct viral behaviours and associated immune signatures. Post-treatment controllers stably aviremic present "silent" humoral profiles, while those virally-exposed develop functionally robust HIV-specific B-cell and antibody responses, which may participate in controlling infection.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
HSP70, His tagged human, recombinant, expressed in baculovirus infected Sf9 cells, ≥70% (SDS-PAGE), buffered aqueous glycerol solution
Sigma-Aldrich
Insulin solution human, sterile-filtered, BioXtra, suitable for cell culture
Sigma-Aldrich
Jo-1 human, recombinant, expressed in E. coli, solution
Sigma-Aldrich
Complement component C1q from human serum, ≥95% (SDS-PAGE)
Sigma-Aldrich
Histone H2b full length human, recombinant, expressed in E. coli, ≥65% (SDS-PAGE)
Sigma-Aldrich
Thyroglobulin human
Sigma-Aldrich
Collagen human, Bornstein and Traub Type I, acid soluble, powder, ~95% (SDS-PAGE)